421
Participants
Start Date
April 30, 2011
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
Nilotinib
This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
Novartis Investigative Site, Taipei
Novartis Investigative Site, Muscat
Novartis Investigative Site, Saida
Novartis Investigative Site, Tunis
Novartis Investigative Site, Soweto
Novartis Investigative Site, St Leonards
Novartis Investigative Site, Concord NSW
Novartis Investigative Site, Westmead
Novartis Investigative Site, Liverpool
Novartis Investigative Site, Parktown
Novartis Investigative Site, Kogarah
Novartis Investigative Site, Gosford
Novartis Investigative Site, Canberra
Novartis Investigative Site, Kingswood
Novartis Investigative Site, Parkville
Novartis Investigative Site, Fitzroy
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Box Hill
Novartis Investigative Site, Clayton
Novartis Investigative Site, Wodonga
Novartis Investigative Site, Sousse
Novartis Investigative Site, Woolloongabba
Novartis Investigative Site, Douglas
Novartis Investigative Site, Adelaide
Novartis Investigative Site, Bedford Park
Novartis Investigative Site, Perth
Novartis Investigative Site, Nedlands
Novartis Investigative Site, Hobart
Novartis Investigative Site, Observatory
Novartis Investigative Site, Bloemfontein
Novartis Investigative Site, Pulau Pinang
Novartis Investigative Site, Riyadh
Novartis Investigative Site, Riyadh
Novartis Investigative Site, Cairo
Novartis Investigative Site, Dammam
Novartis Investigative Site, Algiers
Novartis Investigative Site, Alexandria
Novartis Investigative Site, Jeddah
Novartis Investigative Site, Jeddah
Novartis Investigative Site, Oran
Novartis Investigative Site, Linkou District
Novartis Investigative Site, Al Mansurah
Novartis Investigative Site, Muang
Novartis Investigative Site, Taichung
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Kuala Selangor
Novartis Investigative Site, San Luis Potosí City
Novartis Investigative Site, Hermosillo
Novartis Investigative Site, Niaosong Township
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Arkhangelsk
Novartis Investigative Site, Beirut
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Tula
Novartis Investigative Site, Rostov-on-Don
Novartis Investigative Site, Rostov-on-Don
Novartis Investigative Site, Ryazan
Novartis Investigative Site, Pune
Novartis Investigative Site, Tamil Nadu
Novartis Investigative Site, Nizhny Novgorod
Novartis Investigative Site, Perm
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Tyumen
Novartis Investigative Site, Novosibirsk
Novartis Investigative Site, Vellore
Novartis Investigative Site, Irkutsk
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Jerusalem
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Caba
Novartis Investigative Site, Paraná
Novartis Investigative Site, Salvador
Novartis Investigative Site, Goiânia
Novartis Investigative Site, Curitiba
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Moncton
Novartis Investigative Site, Saint John
Novartis Investigative Site, St. John's
Novartis Investigative Site, Halifax
Novartis Investigative Site, Barrie
Novartis Investigative Site, Brampton
Novartis Investigative Site, Hamilton
Novartis Investigative Site, London
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Toronto
Novartis Investigative Site, Weston
Novartis Investigative Site, Windsor
Novartis Investigative Site, Montreal
Novartis Investigative Site, Québec
Novartis Investigative Site, Saskatoon
Novartis Investigative Site, Cairo
Novartis Investigative Site, Dubai
Novartis Investigative Site, Pretoria
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY